

Sara Bringham

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9354885/publications.pdf>

Version: 2024-02-01

133
papers

8,781
citations

94269

37
h-index

42291

92
g-index

133
all docs

133
docs citations

133
times ranked

5367
citing authors

#	ARTICLE	IF	CITATIONS
1	Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. <i>Leukemia</i> , 2008, 22, 414-423.	3.3	787
2	Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial. <i>Lancet</i> , The, 2006, 367, 825-831.	6.3	775
3	Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report. <i>Blood</i> , 2015, 125, 2068-2074.	0.6	586
4	Lenalidomide Maintenance After Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: A Meta-Analysis. <i>Journal of Clinical Oncology</i> , 2017, 35, 3279-3289.	0.8	535
5	Bortezomib-Melphalan-Prednisone-Thalidomide Followed by Maintenance With Bortezomib-Thalidomide Compared With Bortezomib-Melphalan-Prednisone for Initial Treatment of Multiple Myeloma: A Randomized Controlled Trial. <i>Journal of Clinical Oncology</i> , 2010, 28, 5101-5109.	0.8	400
6	Efficacy and safety of once-weekly bortezomib in multiple myeloma patients. <i>Blood</i> , 2010, 116, 4745-4753.	0.6	361
7	Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: updated results of a randomized controlled trial. <i>Blood</i> , 2008, 112, 3107-3114.	0.6	339
8	Personalized therapy in multiple myeloma according to patient age and vulnerability: a report of the European Myeloma Network (EMN). <i>Blood</i> , 2011, 118, 4519-4529.	0.6	309
9	Intermediate-dose melphalan improves survival of myeloma patients aged 50 to 70: results of a randomized controlled trial. <i>Blood</i> , 2004, 104, 3052-3057.	0.6	305
10	Melphalan, Prednisone, and Lenalidomide Treatment for Newly Diagnosed Myeloma: A Report From the GIMEMA Italian Multiple Myeloma Network. <i>Journal of Clinical Oncology</i> , 2007, 25, 4459-4465.	0.8	301
11	European Myeloma Network Guidelines for the Management of Multiple Myeloma-related Complications. <i>Haematologica</i> , 2015, 100, 1254-1266.	1.7	289
12	Aspirin or enoxaparin thromboprophylaxis for patients with newly diagnosed multiple myeloma treated with lenalidomide. <i>Blood</i> , 2012, 119, 933-939.	0.6	260
13	Second primary malignancies with lenalidomide therapy for newly diagnosed myeloma: a meta-analysis of individual patient data. <i>Lancet Oncology</i> , The, 2014, 15, 333-342.	5.1	256
14	Thalidomide for previously untreated elderly patients with multiple myeloma: meta-analysis of 1685 individual patient data from 6 randomized clinical trials. <i>Blood</i> , 2011, 118, 1239-1247.	0.6	243
15	Bortezomib-Melphalan-Prednisone-Thalidomide Followed by Maintenance With Bortezomib-Thalidomide Compared With Bortezomib-Melphalan-Prednisone for Initial Treatment of Multiple Myeloma: Updated Follow-Up and Improved Survival. <i>Journal of Clinical Oncology</i> , 2014, 32, 634-640.	0.8	198
16	Age and organ damage correlate with poor survival in myeloma patients: meta-analysis of 1435 individual patient data from 4 randomized trials. <i>Haematologica</i> , 2013, 98, 980-987.	1.7	193
17	Bortezomib, melphalan, prednisone, and thalidomide for relapsed multiple myeloma. <i>Blood</i> , 2007, 109, 2767-2772.	0.6	174
18	Bortezomib As Induction Before Autologous Transplantation, Followed by Lenalidomide As Consolidation-Maintenance in Untreated Multiple Myeloma Patients. <i>Journal of Clinical Oncology</i> , 2010, 28, 800-807.	0.8	166

#	ARTICLE	IF	CITATIONS
19	Carfilzomib, cyclophosphamide, and dexamethasone in patients with newly diagnosed multiple myeloma: a multicenter, phase 2 study. <i>Blood</i> , 2014, 124, 63-69.	0.6	126
20	Melphalan 200 mg/m ² versus melphalan 100 mg/m ² in newly diagnosed myeloma patients: a prospective, multicenter phase 3 study. <i>Blood</i> , 2010, 115, 1873-1879.	0.6	87
21	Patient-centered practice in elderly myeloma patients: an overview and consensus from the European Myeloma Network (EMN). <i>Leukemia</i> , 2018, 32, 1697-1712.	3.3	83
22	Triplet vs doublet lenalidomide-containing regimens for the treatment of elderly patients with newly diagnosed multiple myeloma. <i>Blood</i> , 2016, 127, 1102-1108.	0.6	78
23	Lenalidomide and low-dose dexamethasone for newly diagnosed primary plasma cell leukemia. <i>Leukemia</i> , 2014, 28, 222-225.	3.3	77
24	Cardiovascular adverse events in modern myeloma therapy – Incidence and risks. A review from the European Myeloma Network (EMN) and Italian Society of Arterial Hypertension (SIIA). <i>Haematologica</i> , 2018, 103, 1422-1432.	1.7	70
25	Maintenance Treatment and Survival in Patients With Myeloma. <i>JAMA Oncology</i> , 2018, 4, 1389.	3.4	67
26	Melflufen plus dexamethasone in relapsed and refractory multiple myeloma (O-12-M1): a multicentre, international, open-label, phase 1–2 study. <i>Lancet Haematology</i> , 2020, 7, e395-e407.	2.2	65
27	Ixazomib as Postinduction Maintenance for Patients With Newly Diagnosed Multiple Myeloma Not Undergoing Autologous Stem Cell Transplantation: The Phase III TOURMALINE-MM4 Trial. <i>Journal of Clinical Oncology</i> , 2020, 38, 4030-4041.	0.8	56
28	Circulating miRNA markers show promise as new prognosticators for multiple myeloma. <i>Leukemia</i> , 2014, 28, 1922-1926.	3.3	55
29	Intravenous melphalan, thalidomide and prednisone in refractory and relapsed multiple myeloma. <i>European Journal of Haematology</i> , 2006, 76, 273-277.	1.1	51
30	Stem cell mobilization in patients with newly diagnosed multiple myeloma after lenalidomide induction therapy. <i>Leukemia</i> , 2011, 25, 1627-1631.	3.3	51
31	Age and aging in blood disorders: multiple myeloma. <i>Haematologica</i> , 2014, 99, 1133-1137.	1.7	50
32	Isatuximab as monotherapy and combined with dexamethasone in patients with relapsed/refractory multiple myeloma. <i>Blood</i> , 2021, 137, 1154-1165.	0.6	49
33	Melphalan and its role in the management of patients with multiple myeloma. <i>Expert Review of Anticancer Therapy</i> , 2007, 7, 945-957.	1.1	43
34	Bortezomib cumulative dose, efficacy, and tolerability with three different bortezomib-melphalan-prednisone regimens in previously untreated myeloma patients ineligible for high-dose therapy. <i>Haematologica</i> , 2014, 99, 1114-1122.	1.7	42
35	Prevention, monitoring and treatment of cardiovascular adverse events in myeloma patients receiving carfilzomib A consensus paper by the European Myeloma Network and the Italian Society of Arterial Hypertension. <i>Journal of Internal Medicine</i> , 2019, 286, 63-74.	2.7	42
36	New Agents in Multiple Myeloma: An Examination of Safety Profiles. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, 391-407.e5.	0.2	41

#	ARTICLE	IF	CITATIONS
37	Dose/schedule-adjusted Rd-R vs continuous Rd for elderly, intermediate-fit patients with newly diagnosed multiple myeloma. <i>Blood</i> , 2021, 137, 3027-3036.	0.6	40
38	Once-weekly carfilzomib, pomalidomide, and low-dose dexamethasone for relapsed/refractory myeloma: a phase I/II study. <i>Leukemia</i> , 2018, 32, 1803-1807.	3.3	39
39	A phase 2 study of three low-dose intensity subcutaneous bortezomib regimens in elderly frail patients with untreated multiple myeloma. <i>Leukemia</i> , 2016, 30, 1320-1326.	3.3	38
40	Approach to the Older Adult With Multiple Myeloma. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2019, 39, 500-518.	1.8	36
41	Melflufen: A Peptide-Drug Conjugate for the Treatment of Multiple Myeloma. <i>Journal of Clinical Medicine</i> , 2020, 9, 3120.	1.0	35
42	Early Relapse Risk in Patients with Newly Diagnosed Multiple Myeloma Characterized by Next-generation Sequencing. <i>Clinical Cancer Research</i> , 2020, 26, 4832-4841.	3.2	33
43	Multiple myeloma: comparison of two dose-intensive melphalan regimens (100 vs 200 mg/m ²). <i>Leukemia</i> , 2004, 18, 133-138.	3.3	30
44	Efficacy and Feasibility of Dose/Schedule-Adjusted Rd-R Vs. Continuous Rd in Elderly and Intermediate-Fit Newly Diagnosed Multiple Myeloma (NDMM) Patients: RV-MM-PI-0752 Phase III Randomized Study. <i>Blood</i> , 2018, 132, 305-305.	0.6	30
45	Lenalidomide-based induction and maintenance in elderly newly diagnosed multiple myeloma patients: updated results of the EMN01 randomized trial. <i>Haematologica</i> , 2020, 105, 1937-1947.	1.7	29
46	First Results of Iberdomide (IBER; CC-220) in Combination with Dexamethasone (DEX) and Daratumumab (DARA) or Bortezomib (BORT) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM). <i>Blood</i> , 2020, 136, 16-17.	0.6	28
47	Prognostic or predictive value of circulating cytokines and angiogenic factors for initial treatment of multiple myeloma in the GIMEMA MM0305 randomized controlled trial. <i>Journal of Hematology and Oncology</i> , 2019, 12, 4.	6.9	27
48	Isatuximab plus pomalidomide and dexamethasone in elderly patients with relapsed/refractory multiple myeloma: ICARIA-MM subgroup analysis. <i>Haematologica</i> , 2021, 106, 1182-1187.	1.7	27
49	Predicting poor peripheral blood stem cell collection in patients with multiple myeloma receiving pre-transplant induction therapy with novel agents and mobilized with cyclophosphamide plus granulocyte-colony stimulating factor: results from a Gruppo Italiano Malattie Ematologiche dell'Adulto Multiple Myeloma Working Party study. <i>Stem Cell Research and Therapy</i> , 2015, 6, 64.	2.4	25
50	Phase 1/2 study of weekly carfilzomib, cyclophosphamide, dexamethasone in newly diagnosed transplant-ineligible myeloma. <i>Leukemia</i> , 2018, 32, 979-985.	3.3	25
51	Early mortality in myeloma patients treated with first-generation novel agents thalidomide, lenalidomide, bortezomib at diagnosis: A pooled analysis. <i>Critical Reviews in Oncology/Hematology</i> , 2018, 130, 27-35.	2.0	25
52	Intermediate-Dose Melphalan (100 mg/m ²)/Bortezomib/Thalidomide/Dexamethasone and Stem Cell Support in Patients with Refractory or Relapsed Myeloma. <i>Clinical Lymphoma and Myeloma</i> , 2006, 6, 475-477.	1.4	22
53	Once-weekly versus twice-weekly carfilzomib in patients with newly diagnosed multiple myeloma: a pooled analysis of two phase I/II studies. <i>Haematologica</i> , 2019, 104, 1640-1647.	1.7	22
54	Preliminary Results from a Phase I Study of Isatuximab (ISA) in Combination with Bortezomib, Lenalidomide, Dexamethasone (VRd), and in Patients with Newly Diagnosed Multiple Myeloma (NDMM) Non-Eligible for Transplant. <i>Blood</i> , 2018, 132, 595-595.	0.6	22

#	ARTICLE	IF	CITATIONS
55	Update on the use of defibrotide. Expert Opinion on Biological Therapy, 2012, 12, 353-361.	1.4	21
56	Impact of New Drugs on the Long-Term Follow-Up of Upfront Tandem Autograftâ€“Allograft in Multiple Myeloma. Biology of Blood and Marrow Transplantation, 2018, 24, 189-193.	2.0	21
57	Results from a Phase II Study of Isatuximab As a Single Agent and in Combination with Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma. Blood, 2018, 132, 155-155.	0.6	21
58	Cardiovascular Organ Damage and Blood Pressure Levels Predict Adverse Events in Multiple Myeloma Patients Undergoing Carfilzomib Therapy. Cancers, 2019, 11, 622.	1.7	20
59	Lenalidomide and low-dose dexamethasone (Rd) versus bortezomib, melphalan, prednisone (VMP) in elderly newly diagnosed multiple myeloma patients: A comparison of two prospective trials. American Journal of Hematology, 2017, 92, 244-250.	2.0	19
60	Isatuximab plus pomalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma according to prior lines of treatment and refractory status: ICARIA-MM subgroup analysis. Leukemia Research, 2021, 104, 106576.	0.4	19
61	Evaluation of Cardiovascular Toxicity Associated with Treatments Containing Proteasome Inhibitors in Multiple Myeloma Therapy. High Blood Pressure and Cardiovascular Prevention, 2018, 25, 209-218.	1.0	18
62	Pharmacokinetic evaluation of pomalidomide for the treatment of myeloma. Expert Opinion on Drug Metabolism and Toxicology, 2013, 9, 1517-1527.	1.5	17
63	Strategy for the treatment of multiple myeloma utilizing monoclonal antibodies: A new era begins. Leukemia and Lymphoma, 2016, 57, 537-556.	0.6	17
64	Efficacy and safety of carfilzomib-based regimens in frail patients with relapsed and/or refractory multiple myeloma. Blood Advances, 2020, 4, 5449-5459.	2.5	17
65	Elotuzumab, lenalidomide, and dexamethasone as salvage therapy for patients with multiple myeloma: Italian, multicenter, retrospective clinical experience with 300 cases outside of controlled clinical trials. Haematologica, 2020, 106, 291-294.	1.7	17
66	A Phase III Study of Enoxaparin Versus Low-Dose Warfarin Versus Aspirin as Thromboprophylaxis for Patients with Newly Diagnosed Multiple Myeloma Treated up-Front with Thalidomide-Containing Regimens. Blood, 2008, 112, 3017-3017.	0.6	17
67	First-line therapy with either bortezomib-melphalan-prednisone or lenalidomide-dexamethasone followed by lenalidomide for transplant-ineligible multiple myeloma patients: a pooled analysis of two randomized trials. Haematologica, 2020, 105, 1074-1080.	1.7	16
68	Bortezomib, Melphalan, Prednisone and Thalidomide (VMPT) Followed by Maintenance with Bortezomib and Thalidomide for Initial Treatment of Elderly Multiple Myeloma Patients.. Blood, 2009, 114, 128-128.	0.6	16
69	A Simple Score, Based On Geriatric Assessment, Improves Prediction of Survival, and Risk Of Serious Adverse Events In Elderly Newly Diagnosed Multiple Myeloma Patients. Blood, 2013, 122, 687-687.	0.6	15
70	Monoclonal Antibodies to Treat Multiple Myeloma: A Dream Come True. International Journal of Molecular Sciences, 2020, 21, 8192.	1.8	14
71	A Phase III Study of Enoxaparin vs Aspirin vs Low-Dose Warfarin as Thromboprophylaxis for Newly Diagnosed Myeloma Patients Treated with Thalidomide Based-Regimens.. Blood, 2009, 114, 492-492.	0.6	14
72	Monoclonal antibodies currently in Phase II and III trials for multiple myeloma. Expert Opinion on Biological Therapy, 2014, 14, 1127-1144.	1.4	13

#	ARTICLE	IF	CITATIONS
73	Overall Survival Benefit for Bortezomib-Melphalan-Prednisone-Thalidomide Followed by Maintenance with Bortezomib-Thalidomide (VMPT-VT) Versus Bortezomib-Melphalan-Prednisone (VMP) in Newly Diagnosed Multiple Myeloma Patients. <i>Blood</i> , 2012, 120, 200-200.	0.6	13
74	A Randomized Phase 3 Trial Of Melphalan-Lenalidomide-Prednisone (MPR) Or Cyclophosphamide-Prednisone-Lenalidomide (CPR) Vs Lenalidomide Plus Dexamethsone (Rd) In Elderly Newly Diagnosed Multiple Myeloma Patients. <i>Blood</i> , 2013, 122, 536-536.	0.6	13
75	Carfilzomib, cyclophosphamide and dexamethasone for newly diagnosed, high-risk myeloma patients not eligible for transplant: a pooled analysis of two studies. <i>Haematologica</i> , 2021, 106, 1079-1085.	1.7	12
76	How is patient care for multiple myeloma advancing?. <i>Expert Review of Hematology</i> , 2017, 10, 551-561.	1.0	11
77	Systemic virotherapy for multiple myeloma. <i>Expert Opinion on Biological Therapy</i> , 2017, 17, 1-13.	1.4	11
78	Melflufen plus dexamethasone in relapsed/refractory multiple myeloma: long-term survival follow-up from the Phase II study Oâ€œ12â€œM1. <i>British Journal of Haematology</i> , 2021, 193, 1105-1109.	1.2	11
79	A longitudinal analysis of chromosomal abnormalities in disease progression from MGUS/SMM to newly diagnosed and relapsed multiple myeloma. <i>Annals of Hematology</i> , 2021, 100, 437-443.	0.8	11
80	Determining treatment intensity in elderly patients with multiple myeloma. <i>Expert Review of Anticancer Therapy</i> , 2018, 18, 917-930.	1.1	10
81	Isatuximab plus pomalidomide and dexamethasone in frail patients with relapsed/refractory multiple myeloma: <sc>ICARIAâ€œMM</sc> subgroup analysis. <i>American Journal of Hematology</i> , 2021, 96, E423-E427.	2.0	10
82	Evaluation of the pharmacokinetics, preclinical, and clinical efficacy of lenalidomide for the treatment of multiple myeloma. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2012, 8, 1209-1222.	1.5	9
83	Treatment of Newly Diagnosed Elderly Multiple Myeloma. <i>Cancer Treatment and Research</i> , 2016, 169, 123-143.	0.2	9
84	Treatment Intensification With Autologous Stem Cell Transplantation and Lenalidomide Maintenance Improves Survival Outcomes of Patients With Newly Diagnosed Multiple Myeloma in Complete Response. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, 533-540.	0.2	9
85	Multiple Myeloma Patients Undergoing Carfilzomib: Development and Validation of a Risk Score for Cardiovascular Adverse Events Prediction. <i>Cancers</i> , 2021, 13, 1631.	1.7	9
86	The Role of Monoclonal Antibodies in the First-Line Treatment of Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma. <i>Pharmaceuticals</i> , 2021, 14, 20.	1.7	9
87	Safety of Rapid Daratumumab Infusion: A Retrospective, Multicenter, Real-Life Analysis on 134 Patients With Multiple Myeloma. <i>Frontiers in Oncology</i> , 2022, 12, 851864.	1.3	9
88	Effects of Carfilzomib Therapy on Left Ventricular Function in Multiple Myeloma Patients. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 645678.	1.1	8
89	Circulating Mir-16 and Mir-25 As New Prognosticators For Multiple Myeloma. <i>Blood</i> , 2013, 122, 1853-1853.	0.6	8
90	A Phase II Study With Carfilzomib, Cyclophosphamide and Dexamethasone (CCd) For Newly Diagnosed Multiple Myeloma. <i>Blood</i> , 2013, 122, 685-685.	0.6	8

#	ARTICLE	IF	CITATIONS
91	Octogenarian newly diagnosed multiple myeloma patients without geriatric impairments: the role of age >80 in the IMWG frailty score. <i>Blood Cancer Journal</i> , 2021, 11, 73.	2.8	7
92	Long Term Outcome of Lenalidomide-Dexamethasone (Rd) Vs Melphalan-Lenalidomide-Prednisone (MPR) Vs Cyclophosphamide-Prednisone-Lenalidomide (CPR) As Induction Followed By Lenalidomide-Prednisone (RP) Vs Lenalidomide (R) As Maintenance in a Community-Based Newly Diagnosed Myeloma Population: Updated Analysis of EMN01 Phase III Study. <i>Blood</i> , 2017, 130, 901-901.	0.6	7
93	Current Phase II investigational proteasome inhibitors for the treatment of multiple myeloma. <i>Expert Opinion on Investigational Drugs</i> , 2014, 23, 1193-1209.	1.9	6
94	Updated results of a phase 2 study of panobinostat combined with melphalan, thalidomide and prednisone (MPT) in relapsed/refractory multiple myeloma. <i>Leukemia and Lymphoma</i> , 2018, 59, 1271-1273.	0.6	6
95	Isatuximab for relapsed/refractory multiple myeloma: review of key subgroup analyses from the Phase III ICARIA-MM study. <i>Future Oncology</i> , 2021, 17, 4797-4812.	1.1	6
96	Bortezomib-Based Induction Treatments Improve Outcomes of Newly Diagnosed Multiple Myeloma Patients with High-Risk Cytogenetic Abnormalities. <i>Blood</i> , 2010, 116, 781-781.	0.6	6
97	A Multicenter, Open Label Phase I/II Study of Carfilzomib, Pomalidomide and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma (MM) Patients. <i>Blood</i> , 2016, 128, 1145-1145.	0.6	6
98	Second primary malignancies (SPM) in newly diagnosed myeloma (MM) patients treated with lenalidomide (Len): Meta-analysis of 6,383 individual patient data (IPD).. <i>Journal of Clinical Oncology</i> , 2013, 31, 8517-8517.	0.8	6
99	Clinical and Pharmacologic Features of Monoclonal Antibodies and Checkpoint Blockade Therapy in Multiple Myeloma. <i>Current Medicinal Chemistry</i> , 2019, 26, 5968-5981.	1.2	6
100	Progression-Free Survival (PFS) Benefit Demonstrated and Quality of Life (QoL) Maintained across Age and Frailty Subgroups with the Oral Proteasome Inhibitor (PI) Ixazomib Vs Placebo As Post-Induction Maintenance Therapy in Non-Transplant Newly Diagnosed Multiple Myeloma (NDMM) Patients (Pts): Analysis of the TOURMALINE-MM4 Phase 3 Trial. <i>Blood</i> , 2020, 136, 30-31.	0.6	6
101	Elotuzumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended 3-year follow-up of a multicenter, retrospective clinical experience with 319 cases outside of controlled clinical trials. <i>Hematological Oncology</i> , 2022, 40, 704-715.	0.8	6
102	The Weekly Infusion of Bortezomib Reduces Peripheral Neuropathy.. <i>Blood</i> , 2009, 114, 3887-3887.	0.6	5
103	Doublet Vs Triplet Lenalidomide-Containing Regimens in Newly Diagnosed Myeloma Patients, Younger or Older Than 75 Years: Subgroup Analysis of a Phase III Study. <i>Blood</i> , 2014, 124, 2110-2110.	0.6	5
104	Ixazomib vs placebo maintenance for newly diagnosed multiple myeloma (NDMM) patients not undergoing autologous stem cell transplant (ASCT): The phase III TOURMALINE-MM4 trial.. <i>Journal of Clinical Oncology</i> , 2020, 38, 8527-8527.	0.8	5
105	Updates from a phase Ib study of isatuximab (Isa), bortezomib (V) and dexamethasone (D) plus cyclophosphamide (C) or lenalidomide (R) in transplant-ineligible, newly diagnosed multiple myeloma (NDMM).. <i>Journal of Clinical Oncology</i> , 2020, 38, 8529-8529.	0.8	5
106	Adjusted comparison between elotuzumab and carfilzomib in combination with lenalidomide and dexamethasone as salvage therapy for multiple myeloma patients. <i>European Journal of Haematology</i> , 2022, 108, 178-189.	1.1	5
107	Ixazomib-based induction regimens plus ixazomib maintenance in transplant-ineligible, newly diagnosed multiple myeloma: the phase II, multi-arm, randomized UNITO-EMN10 trial. <i>Blood Cancer Journal</i> , 2021, 11, 197.	2.8	5
108	Role of thalidomide in previously untreated patients with multiple myeloma. <i>Expert Review of Anticancer Therapy</i> , 2008, 8, 1569-1580.	1.1	4

#	ARTICLE	IF	CITATIONS
109	New drugs in early development for treating multiple myeloma: all that glitters is not gold. Expert Opinion on Investigational Drugs, 2020, 29, 989-1004.	1.9	4
110	Carfilzomib, Cyclophosphamide and Dexamethasone (CCd) for Newly Diagnosed Multiple Myeloma (MM) Patients. Blood, 2012, 120, 730-730.	0.6	4
111	Weekly Carfilzomib, Cyclophosphamide and Dexamethasone (wCCd) in Newly Diagnosed Multiple Myeloma Patients: A Phase I- II Study. Blood, 2014, 124, 175-175.	0.6	4
112	Weekly Carfilzomib, Cyclophosphamide and Dexamethasone (wCCyd) in Elderly Newly Diagnosed Multiple Myeloma Patients: Results of a Phase 2 Study. Blood, 2015, 126, 1828-1828.	0.6	4
113	Autologous Transplantation Versus Cyclophosphamide-Lenalidomide-Prednisone Followed By Lenalidomide-Prednisone Versus Lenalidomide Maintenance in Multiple Myeloma: Long-Term Results of a Phase III Trial. Blood, 2015, 126, 392-392.	0.6	4
114	Carfilzomib combination treatment as first-line therapy in multiple myeloma: where do we go from the Carhadex (KTd)-trial update?. Haematologica, 2019, 104, 2128-2131.	1.7	3
115	Efficacy of Isatuximab with Pomalidomide and Dexamethasone in Elderly Patients with Relapsed/Refractory Multiple Myeloma: Icaria-MM Subgroup Analysis. Blood, 2019, 134, 1893-1893.	0.6	3
116	Second Primary Malignancies in Newly Diagnosed Multiple Myeloma Patients Treated with Lenalidomide: Analysis of Pooled Data in 2459 Patients. Blood, 2011, 118, 996-996.	0.6	3
117	Salvage therapy in first relapse: a retrospective study in a large patient population with multiple myeloma. European Journal of Haematology, 2017, 98, 289-295.	1.1	2
118	Clinical Outcomes According to Genomic Abnormalities in 566 Newly Diagnosed Multiple Myeloma Patients Treated with Bortezomib-Based Regimens.. Blood, 2009, 114, 1868-1868.	0.6	2
119	Long-Term Follow up of a Comparison of Non-Myeloablative Allografting with Autografting for Newly Diagnosed Myeloma. Blood, 2010, 116, 525-525.	0.6	2
120	Impact of Complete Response on Survival with Either Autologous Stem Cell Transplantation or Conventional Chemotherapy: Results of a Pooled Analysis of 5 Phase III Trials in Newly Diagnosed Multiple Myeloma Patients. Blood, 2015, 126, 927-927.	0.6	2
121	Isatuximab plus pomalidomide and dexamethasone in elderly patients with relapsed/refractory multiple myeloma: ICARIA-MM subgroup analysis. Haematologica, 2022, 107, 774-775.	1.7	2
122	Bortezomib, melphalan, and prednisone in elderly relapsed/refractory multiple myeloma patients: update of multicenter, open-label Phase 1/2 study. Leukemia and Lymphoma, 2017, 58, 2738-2740.	0.6	1
123	Updated Progression-Free Survival (PFS) and Overall Survival (OS) with Melflufen and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Results from the Phase 2 Study O-12-M1. Blood, 2019, 134, 1839-1839.	0.6	1
124	Sequential Approach with Bortezomib as Induction Before Autologous Transplantation, Followed by Lenalidomide as Consolidation-Maintenance in Untreated Multiple Myeloma Patients.. Blood, 2009, 114, 3419-3419.	0.6	1
125	Bortezomib as Front-Line Therapy in Primary Plasma Cell Leukemia. Blood, 2008, 112, 2784-2784.	0.6	1
126	MP0250 Combined with Bortezomib and Dexamethasone in Multiple Myeloma Patients Previously Exposed to Proteasome Inhibitors and Immunomodulatory Drugs. Blood, 2018, 132, 1980-1980.	0.6	1

#	ARTICLE	IF	CITATIONS
127	Does Heparin Have An Anti-Myeloma Effect? An Analysis On Individual Data From Three Randomized Studies of GIMEMA, Nordic and Turkish Myeloma Study Groups,. Blood, 2011, 118, 3970-3970.	0.6	0
128	miRNA in Serum and Bone Marrow Plasma Cells From Multiple Myeloma Patients.. Blood, 2012, 120, 2921-2921.	0.6	0
129	The Combination of Frailty and ISS Scores Identifies a Simple Prognostic Index for Overall Survival in Elderly Patients Treated with Novel Agents-Based Induction Therapy. Blood, 2014, 124, 4740-4740.	0.6	0
130	Prolonged Follow-up Confirmed a Role for Upfront Tandem Auto-Allo Transplant in Multiple Myeloma Also in the Era of New Drugs. Blood, 2016, 128, 3469-3469.	0.6	0
131	An Integrated Analysis of Cardio-Vascular Adverse Events of Carfilzomib, Cyclophosphamide and Dexamethasone in Elderly Newly Diagnosed Myeloma Patients Enrolled in 3 Phase I/II Trials. Blood, 2016, 128, 3336-3336.	0.6	0
132	Impact of Treatment Intensification According to Patient Prognosis: A Pooled Analysis of 3 Randomized Phase III Trials. Blood, 2016, 128, 995-995.	0.6	0
133	Cost efficiency and effectiveness of biosimilar filgrastim in autologous transplant. Bone Marrow Transplantation, 2021, , .	1.3	0